Clinical validation of statistical predictive model for patient-specific quality assurance outcomes in stereotactic radiotherapy using secondary Monte Carlo dose calculations

Phillip Wall, Wes Tucker, Thomas Mazur, Frank Marshall, Jonathan Pence, Jon Hansen, Michael Prusator, Matthew Schmidt, Nels Knutson

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate Monte Carlo (MC) secondary dose verification for predicting ionization chamber (IC)-based patient-specific quality assurance (PSQA) measurements for stereotactic body radiotherapy (SBRT) plans. Methods: IC-based PSQA is a trusted method for verifying accurate delivery of absolute dose calculated by the treatment planning system (TPS). However, these measurements are often time-consuming and challenging to perform precisely, especially for small-volume SBRT targets. To investigate an MC-based method as a viable alternative, a logistic regression model was developed to predict measurement-based PSQA results utilizing 400 retrospectively collected IC PSQA measurements across our system. Each clinically approved plan was recalculated using a commercially available secondary MC-based dose calculation platform (Rad MonteCarlo, Radformation, NY). The dose to a contoured volume corresponding to the active IC volume was recorded. Additionally, measurement setup uncertainty was modeled by placing equivalent volumes +/- 2 mm in each cardinal direction. The TPS-calculated value was compared to the average MC-simulated values for all contours. Receiver Operating Characteristic (ROC) analysis was performed on an additional dataset of 328 prospective PSQA measurements to determine MC-based QA prediction thresholds for indicating when physical measurements can be safely avoided. Results: Of the 400 model plans, the percent differences between IC and TPS doses were [Median: −0.06%, Range: −19.6%-4.5%]. The percent differences between IC and MC doses were [Median: 0.17%, Range: −21.8%-5.1%]. When investigating MC against TPS dose for predicting likely PSQA failures, ROC analysis yielded an AUC of 0.76. Based on threshold analysis of the prospective validation dataset, a difference of 1% between MC and TPS calculations resulted in zero false negatives, and would safely reduce the number of required IC measurements by 46%. Conclusion: This study demonstrates feasibility of and a workflow for implementing MC-based secondary dose calculations to reduce the number of physical measurements required for PSQA without compromising safety and quality.

Original languageEnglish
Article number110934
JournalRadiotherapy and Oncology
Volume208
DOIs
StatePublished - Jul 2025

Keywords

  • Independent secondary dose verification
  • Monte Carlo
  • Patient-specific quality assurance
  • SBRT
  • Statistical modeling

Fingerprint

Dive into the research topics of 'Clinical validation of statistical predictive model for patient-specific quality assurance outcomes in stereotactic radiotherapy using secondary Monte Carlo dose calculations'. Together they form a unique fingerprint.

Cite this